


(Signature of person mailing)

Erica L. Smith

(Typed or printed name of person)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Laura C. Blumberg, et al.

Serial No.: 10/660,052

Filed: September 10, 2003

Title: NOVEL PIPERAZINE
DERIVATIVES

Group Art Unit: 1624

Examiner: Emily B. Bernhardt

**Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450**

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Sir:

Applicants hereby submit to the U.S. Patent and Trademark Office form PTO-FB-A820 and a copy of the documents cited therein excluding the currently cited U.S. patents pursuant to the current waiver of the requirement under 37 C.F.R. § 1.98(a)(2)(i) to ensure compliance with the continuing duty of candor as set forth in 37 C.F.R. § 1.56. 1276 Off. Gaz. Pat. Office 55 (05 Aug. 2003). This submission is intended to augment, and not replace, the Information Disclosure Statement filed previously on December 11, 2003.


In the judgment of the undersigned, portions of the documents cited in form PTO-FB-A820 may be material to the present application, however, the filing of this Information Disclosure Statement shall not be construed to be an admission that the documents

cited are, or are considered to be, material with regard to patentability as defined in 37 C.F.R. § 1.56(b). The documents have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative importance of any portion of the documents. This statement is not a representation that the listed documents have an effective date early enough to be "prior art" within the meaning of 35 U.S.C. § 102 or § 103.

As this Information Disclosure Statement is being filed before the mailing of a first Office Action after the filing of a request for continued examination, Applicants believe that no fee is due pursuant to 37 C.F.R. § 1.97(b)(4). However, to the extent a fee is necessary, please apply any charges or credits to Deposit Account No. 16-1445.


Respectfully submitted,

Date: June 23, 2005


Christopher J. Verni
Attorney for Applicants
Reg. No. 48,322

Customer No. 28523
Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 686-2032

Doc. #: 83097v1



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)									ATTY. DOCKET NO. PC10770B			SERIAL NO. 10/660,052					
									APPLICANT Laura C. Blumberg, et al.								
									FILING DATE September 10, 2003			GROUP 1624					
U.S. PATENT DOCUMENTS																	
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE				
	US	5	3	4	4	5	5	8	4/19/94	Kaneko, et al.	514	253					
	US	5	6	9	1	3	4	0	11/25/97	Baziar-Mouysset et al.	514	253					
FOREIGN PATENT DOCUMENTS																	
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION				
													YES	NO			
	WO	9	5	0	1	3	4	9	01/12/95	International	C07D	237/22					
	WO	99	0	0	6	3	8	4	2/11/99	International	C07D	295/12					
	EP	9	0	2	4	5	8	8	5/13/94	European	C07D	403/08					
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)																	
			Liang, M., et al. <u>Journal of Biological Chemistry</u> , "Identification and Characterization of a Potent, Selective, and Orally Active Antagonist of the CC Chemokine Receptor-1", Vol. 275, No. 25, pages 19000-19008 (2000)														
EXAMINER																	
DATE CONSIDERED																	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.																	